Growth hormone therapy: Comparison of short- and long-term outcomes between children with Growth Hormone Deficiency and Small for Gestational Age.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-04-18 DOI:10.1159/000538798

Andreas Gleiss, A. Raimann, Florentina Haufler, D. Ertl, S. Sagmeister, Gabriele Hartmann

{"title":"Growth hormone therapy: Comparison of short- and long-term outcomes between children with Growth Hormone Deficiency and Small for Gestational Age.","authors":"Andreas Gleiss, A. Raimann, Florentina Haufler, D. Ertl, S. Sagmeister, Gabriele Hartmann","doi":"10.1159/000538798","DOIUrl":null,"url":null,"abstract":"Introduction Direct comparisons of both short-term and long-term auxological outcome of growth hormone therapy (GHT) between growth hormone deficiency (GHD) and small for gestational age (SGA) are scarce. Methods 103 patients with GHD and 53 patients with SGA treated at our tertiary center were investigated. Short-term and long-term outcomes were compared between these groups using multi-variable linear regression models with adjustment for age, sex and height at therapy start, also allowing for sex-specific group comparisons. Results Mean delta height standard deviation scores (SDS) after 1 year of treatment was significantly higher in GHD (0.90, CI 0.82 to 0.99) compared to SGA (0.67, C I 0.54 to 0.79)(p= 0.003) with no sex difference. As expected, the mean increase in height SDS at final height (FH) was significantly higher in GHD (2.21, CI 2.00 to 2.42) compared to SGA (1.05, CI 0.75 to 1.35)(p<0.001), leading to a target height corrected FH of -0.39 SDS (CI -0.62 to -0.15) in GHD and -1.22 SDS (CI-1.57 to -0.87) in SGA ( p<0.001). Girls with GHD had a better long-term outcome, as did boys with SGA when compared to the respective opposite sex. The cut-off of delta height of 0.5 SDS during the first year had a low sensitivity to detect long-term non-responders. We found a relation between short-term and long-term outcome in GHD, but not in SGA (adjusted R2 = 0.66 vs. 0.01). Conclusion In contrast to GHD, we observed practically no relationship between 1st-year and long-term outcome in SGA patients treated with GH.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":" 10","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000538798","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction Direct comparisons of both short-term and long-term auxological outcome of growth hormone therapy (GHT) between growth hormone deficiency (GHD) and small for gestational age (SGA) are scarce. Methods 103 patients with GHD and 53 patients with SGA treated at our tertiary center were investigated. Short-term and long-term outcomes were compared between these groups using multi-variable linear regression models with adjustment for age, sex and height at therapy start, also allowing for sex-specific group comparisons. Results Mean delta height standard deviation scores (SDS) after 1 year of treatment was significantly higher in GHD (0.90, CI 0.82 to 0.99) compared to SGA (0.67, C I 0.54 to 0.79)(p= 0.003) with no sex difference. As expected, the mean increase in height SDS at final height (FH) was significantly higher in GHD (2.21, CI 2.00 to 2.42) compared to SGA (1.05, CI 0.75 to 1.35)(p<0.001), leading to a target height corrected FH of -0.39 SDS (CI -0.62 to -0.15) in GHD and -1.22 SDS (CI-1.57 to -0.87) in SGA ( p<0.001). Girls with GHD had a better long-term outcome, as did boys with SGA when compared to the respective opposite sex. The cut-off of delta height of 0.5 SDS during the first year had a low sensitivity to detect long-term non-responders. We found a relation between short-term and long-term outcome in GHD, but not in SGA (adjusted R2 = 0.66 vs. 0.01). Conclusion In contrast to GHD, we observed practically no relationship between 1st-year and long-term outcome in SGA patients treated with GH.

查看原文本刊更多论文

生长激素疗法：生长激素缺乏症和小于胎龄儿童的短期和长期疗效比较。

导言：生长激素缺乏症（GHD）和小于胎龄儿（SGA）之间生长激素治疗（GHT）的短期和长期辅助治疗效果的直接比较很少见。方法调查了在我们的三级中心接受治疗的 103 名 GHD 患者和 53 名 SGA 患者。采用多变量线性回归模型对这两组患者的短期和长期疗效进行了比较，并对开始治疗时的年龄、性别和身高进行了调整，还对特定性别组进行了比较。结果 GHD（0.90，CI 0.82 至 0.99）治疗 1 年后的平均身高标准偏差（SDS）显著高于 SGA（0.67，C I 0.54 至 0.79）（p= 0.003），且无性别差异。不出所料，与 SGA（1.05，CI 0.75 至 1.35）（p＜0.001）相比，GHD 最终身高（FH）的平均身高 SDS 增长率（2.21，CI 2.00 至 2.42）明显更高，导致 GHD 的目标身高校正 FH 为 -0.39 SDS（CI -0.62 至 -0.15），SGA 为 -1.22 SDS（CI-1.57 至 -0.87）（p＜0.001）。与异性相比，GHD女孩的长期预后较好，SGA男孩也是如此。第一年的身高δ值为 0.5 SDS 时，检测长期无应答者的灵敏度较低。我们发现 GHD 患者的短期结果与长期结果之间存在关系，而 SGA 患者则没有这种关系（调整后的 R2 = 0.66 vs. 0.01）。结论与 GHD 相反，我们发现接受 GH 治疗的 SGA 患者第一年的疗效与长期疗效之间几乎没有关系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464

期刊介绍： ACS Applied Bio Materials is an interdisciplinary journal publishing original research covering all aspects of biomaterials and biointerfaces including and beyond the traditional biosensing, biomedical and therapeutic applications. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrates knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important bio applications. The journal is specifically interested in work that addresses the relationship between structure and function and assesses the stability and degradation of materials under relevant environmental and biological conditions.